Physician profile
Cheryl Brody
NPI 1891788691
$824.82
in general payments reported to CMS, 2019-2025
13 companies · $42.07 in 2025
The $42.07 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $124 · 2021: $325 · 2022: $61.24 · 2023: $48.60 · 2024: $81.92 · 2025: $42.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $256.23 | 2019-2024 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.76 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $109.08 | 2021 | |
| Amgen INC. | $57.52 | 2020-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $55.09 | 2019-2020 | |
| Amarin Pharma, INC. | $44.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.07 | 2025 | |
| Edwards Lifesciences Corporation | $23.81 | 2024 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $23.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2024 | Jardiance |
| Pfizer INC. | $14.10 | 2023 | |
| Nalpropion Pharmaceuticals LLC | $12.51 | 2019 | |
| Merck Sharp & Dohme LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.